ResMed (RMD) Stock Buyback History
TTM buyback yield 1.42% · Shareholder yield (TTM) 1.42%.
ResMed
RMD
TTM buyback yield
1.42%
Shareholder yield (TTM)
1.42%
5Y share count change
1.2%
TTM buyback spend
$500.06M
SBC coverage (TTM)
5.05x
Diluted vs basic shares (annual)
Weighted average shares from the income statement: diluted (EPS denominator and typical buyback-yield basis) compared with basic.
Shares outstanding (annual)
Year-over-year change in diluted weighted average shares (industry-standard for EPS and per-share capital return). Green is fewer shares vs the prior fiscal year; red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield
Buybacks vs stock-based compensation
TTM coverage: 5.05x (buybacks ÷ SBC). Bars are fiscal-year totals.
Buyback spending history
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $300.02M | $91.66M | $208.36M | 0.15B | -0.1% | 0.79% |
| 2024 | $150.01M | $80.18M | $69.83M | 0.15B | 0.1% | 0.55% |
| 2023 | $0.00 | $71.14M | −$71.14M | 0.15B | 0.3% | — |
| 2022 | $0.00 | $65.26M | −$65.26M | 0.15B | 0.4% | — |
| 2021 | $0.00 | $63.93M | −$63.93M | 0.15B | 0.5% | — |
| 2020 | $0.00 | $57.56M | −$57.56M | 0.15B | 0.8% | — |
| 2019 | $22.84M | $52.07M | −$29.23M | 0.14B | 0.3% | 0.13% |
| 2018 | $53.80M | $48.41M | $5.39M | 0.14B | 1.1% | 0.36% |
| 2017 | $0.00 | $45.92M | −$45.92M | 0.14B | 0.6% | — |
| 2016 | $102.06M | $46.41M | $55.65M | 0.14B | -0.7% | 1.15% |
| 2015 | $160.30M | $47.85M | $112.44M | 0.14B | -1.2% | 2.02% |
| 2014 | $202.17M | $43.46M | $158.71M | 0.14B | -1.4% | 2.84% |
| 2013 | $186.26M | $38.16M | $148.10M | 0.15B | -1.9% | 2.92% |
| 2012 | $392.74M | $30.59M | $362.16M | 0.15B | -5.0% | 8.82% |
| 2011 | $163.34M | $30.81M | $132.53M | 0.16B | 1.4% | 3.46% |
| 2010 | $131.08M | $29.73M | $101.35M | 0.16B | 0.6% | 2.85% |
| 2009 | $68.59M | $25.52M | $43.08M | 0.15B | -2.0% | 2.24% |
| 2008 | $96.56M | $0.00 | $96.56M | 0.16B | 0.6% | 3.57% |
| 2007 | $2.09M | $0.00 | $2.09M | 0.16B | 1.4% | 0.07% |
| 2006 | $0.00 | $0.00 | $0.00 | 0.15B | 3.0% | — |
| 2005 | $10.97M | $0.00 | $10.97M | 0.15B | 6.7% | 0.48% |
| 2004 | $19.03M | $0.00 | $19.03M | 0.14B | 2.0% | 1.10% |
| 2003 | $3.54M | $0.00 | $3.54M | 0.14B | 1.1% | 0.27% |
| 2002 | $7.87M | $0.00 | $7.87M | 0.14B | 1.8% | 0.86% |
| 2001 | $0.00 | $0.00 | $0.00 | 0.13B | 3.7% | — |
| 2000 | $0.00 | $0.00 | $0.00 | 0.13B | 4.0% | — |
| 1999 | $0.00 | $0.00 | $0.00 | 0.12B | 3.3% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.12B | 2.7% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.12B | 4.1% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.11B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $300.00K | $0.00 | $300.00K | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
TTM buybacks vs headroom (FCF − dividends, TTM)34% of headroom
Headroom $1.46B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Does ResMed buy back its own stock?
- Yes, ResMed (RMD) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does ResMed spend on share buybacks?
- Trailing twelve months (TTM) buyback spend is about $500.06M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is ResMed's buyback yield?
- TTM buyback yield is about 1.42% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is ResMed's shareholder yield?
- Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 1.42% combined (TTM-based where available).
Is ResMed diluting shareholders?
- Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has ResMed's share count changed?
- Diluted weighted average shares changed by about 1.2% over roughly five fiscal years (annual income statement data).